Compared to more rare mutations in the RAS family, activating mutations of the PI3K-Akt axis appear in approximately 20% of bladder carcinomas, conferring resistance to FGFR inhibitors. This evidence concerns the gene PIK3CA and urinary bladder carcinoma.